What one share of SCYNEXIS holds
SCYNEXIS, Inc. is dedicated to advancing innovative solutions for severe rare diseases, with our lead program in the treatment and prevention of difficult-to-treat and drug-resistant fungal infections.
SCYNEXIS’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.50 |
|---|---|
| Profit | −$1.33 |
| Cash and investments | $1.05 |
| Book value | $6.73 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2014 | $158.14 | −$214.88 | $9.49 | −$137.12 | — | $314.20 |
| 2015 | $1.69 | −$214.56 | $3.87 | −$165.31 | — | $241.34 |
| 2016 | $1.08 | −$126.04 | $0.11 | −$123.48 | — | $113.19 |
| 2017 | $0.77 | −$74.96 | $0.01 | −$73.45 | — | $59.12 |
| 2018 | $0.47 | −$22.73 | $1.03 | −$52.66 | — | $52.07 |
| 2019 | $0.17 | −$76.62 | $0.00 | −$54.38 | — | $10.59 |
| 2020 | $0.00 | −$41.18 | $0.00 | −$36.83 | — | $9.26 |
| 2021 | $3.99 | −$9.97 | $0.00 | −$16.54 | — | $11.50 |
| 2022 | $0.96 | −$11.79 | — | — | — | $0.79 |
| 2023 | $23.17 | $11.08 | — | — | — | $15.69 |
| 2024 | $0.62 | −$3.51 | — | — | — | $11.60 |
| 2025 | $3.30 | −$1.38 | — | — | — | $9.07 |
Common questions about SCYNEXIS
How much does one share of SCYNEXIS earn?
Over the last 12 months, SCYNEXIS lost $1.33 for each share on $2.50 of sales.
Does SCYNEXIS pay a dividend?
SCYNEXIS didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is SCYNEXIS’s book value per share?
SCYNEXIS’s book value is $6.73 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of SCYNEXIS have?
Each share of SCYNEXIS has $1.05 of cash and investments, as of June 30, 2026.
Has SCYNEXIS bought back shares?
SCYNEXIS’s share count rose about 8310% from 2014 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.